- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Ira Klein, MD, MBA, FACP Discusses How Payers Can Offer More Personalized Cancer Care to Oncologists
Ira Klein, MD, MBA, FACP, chief medical officer, National Accounts Clinical Sales & Strategy, Aetna, suggests that oncology practices lack a sense of economic perspective that would otherwise allow them to offer a variety of services to their patients.
Ira Klein, MD, MBA, FACP, chief medical officer, National Accounts Clinical Sales & Strategy, Aetna, suggests that oncology practices lack a sense of economic perspective that would otherwise allow them to offer a variety of services to their patients. He explains that due to size and areas of focus, practices are unable to generate the infrastructure they would like, which is where the payers can assist.
“The help that’s given in the form of software, practice guidelines, maybe even some coaching on how to be an oncology medical home — those are very valuable assets and very useful products that practices could get and payers by doing it are helping both the practices and themselves,” Dr Klein says.
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
